Thomas K. Eigentler
Expertise in
9
conditions

Thomas K. Eigentler

Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
Expertise in
9
conditions
Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 

Overview

Thomas Eigentler practices practicing medicine in Tuebingen, Germany.

Mr. Eigentler is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Melanoma, Adenoid Cystic Carcinoma, Merkel Cell Carcinoma, and Actinic Keratosis.

He is actively involved in clinical research, co-authoring 254 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma
A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug, Other
Study Drug: Dupilumab
Study Phase: Phase 2
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Drug
Study Drug: Vismodegib
Study Phase: Phase 2
Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma
Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

254 Total Publications

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.
Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.
Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
Published: August 16, 2026

Frequently Asked Questions about Thomas K. Eigentler

Is Thomas K. Eigentler a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas K. Eigentler is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas K. Eigentler participate in research or clinical trials?

Yes. Thomas K. Eigentler has published 254 articles and abstracts on conditions like Melanoma. You can view a list of Thomas K. Eigentler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eigentler's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile